Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma
NL-OMON59733Phase 2Active, not recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Dec 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide in multiple myeloma (MM) (3 arms), sponsored by European Myeloma Network B.V. Primary endpoint: Response improvement rate within 6 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59733.